Cardiovascular • May 1-3, 2017
Boston, MA • United States

Tassos Gianakakos

  • CEO, MyoKardia

Tassos Gianakakos joined MyoKardia in October 2013, bringing more than 17 years of senior leadership experience and business development and finance expertise in the biopharmaceutical industry to the company. He joined MyoKardia from MAP Pharmaceuticals (acquired by Allergan in March 2013), where he was most recently senior vice president and chief business officer. In this position, Mr. Gianakakos played an integral role in advancing the company’s two Phase 3 clinical programs and regulatory filings for LEVADEX®, and led the successful co-promotion partnership agreement for the program with Allergan, as well as a global partnership with AstraZeneca for the company’s Unit Dose Budesonide program. Prior to MAP, Mr. Gianakakos led the formation of Codexis, Inc., a spin-off of Maxygen, Inc., in 2001. At Codexis, Mr. Gianakakos served as president and senior vice president, business development, and global head of Codexis’ Pharmaceuticals Business Unit. Before forming Codexis, Mr. Gianakakos was director of business development at Maxygen, where he led the company’s business development efforts for its vaccine and bio-industrial platforms, as well as financing activities including the company’s initial public offering. Prior to Maxygen, Mr. Gianakakos was a process engineer in Merck & Co.’s vaccine division.

Mr. Gianakakos holds B.Sc. degrees in chemical engineering and economics from the Massachusetts Institute of Technology, an M.Sc. in biotechnology from Northwestern University and an M.B.A. from Harvard Business School.

This speaker appears at this event: